Seattle, June 6, 2025

Know Labs, Inc. (NYSE American: Knw), a company focused on non-invasive health monitoring technologies, has announced that it has reached an agreement with Goldeneye 1995 LLC, associated with Greg Kidd, who is a fintech investor and former chief risk officer at Ripple.

According to the deal, the Buyer will take on ownership of common stock by converting a total of 1,000 Bitcoin alongside cash to address current obligations, redeem preferred shares, and secure additional working capital. The inclusion of Bitcoin aligns with the company’s financial strategy, giving investors substantial exposure to this popular digital currency.

“We are thrilled to implement our Bitcoin strategy with the backing of forward-thinking organizations like Know Labs, especially when the market and regulatory landscape seems favorable,” Kidd commented. He expressed confidence that this method would foster sustainable growth and enhance shareholder value, noting that his team possesses considerable expertise in digital assets. This agreement aims to transition existing Bitcoin yield generation strategies to the open market.

Bitcoin holdings will become a central aspect of the company’s balance sheet, and management will utilize the Net Asset Value (MNAV) metric to gauge how the company’s valuation compares to its Bitcoin reserves. At a market cap of $128 million, the MNAV multiple indicates a value of 1.22 times, with Bitcoin holdings comprising 82% of the market cap, assuming Bitcoin is priced at $105,000.

Ron Erickson, the founder, will lead a new division that will support ongoing diagnostic research at the company. After the transaction is finalized, he will transition to vice president of the board. Erickson remarked, “This partnership with Greg Kidd is a pivotal moment for Know Labs. We’re eager to advance our research in non-invasive medical technology, and we believe Greg’s leadership will guide us into a promising future.”

The board of Know Labs has unanimously approved the transaction, which is anticipated to conclude in the third quarter of 2025, pending shareholder approval and fulfillment of standard closing conditions.

Cohen & Company Capital Markets acts as the exclusive financial advisor, while Lowenstein Sandler LLP advises the buyer legally. Sichenzia Ross Ference Carmel LLP serves as the company’s legal counsel.

Greg Kidd co-founded and leads a venture capital firm called Hard Yaka and holds a majority stake in Vast Bank, an OCC-chartered institution. His early investments include major names like Twitter, Square, Coinbase, Robinhood, and Solana. Kidd previously worked at Booz Allen Hamilton and made his mark by facilitating initial public offerings in the 90s. His experience extends to roles at the Federal Reserve and Promontory Financial Group, and he notably served as Ripple’s Chief Risk Officer. Kidd holds degrees from Brown University, Yale University, and Harvard University, and he ran as a nonpartisan candidate for Congress in Nevada’s second district in 2024.

Know Labs, Inc. is publicly traded under the NYSE American Exchange with the symbol “KNW.” The company’s technology, which utilizes spectroscopy, has the potential for various applications, including non-invasive glucose monitors. These devices promise accessible, real-time blood sugar information but will require FDA approval for market introduction.

This communication surrounds the proposed transaction between Know Labs and the buyer. A current report on Form 8-K will be filed and additional documents will be submitted to the U.S. Securities and Exchange Commission, but this communication doesn’t replace any of those official statements. Investors are encouraged to review these documents for complete information.

Information about Know Labs’ directors and executives, stock ownership, and related party transactions can be found in its annual reports. These documents are accessible without charge from specified sources.

This communication is for informational purposes and does not constitute an offer or solicitation for purchase or sale of securities.

Some statements made here are forward-looking and should not be relied upon, as actual results may differ due to various uncertainties and risks involved in the company’s operations.